BrainBike peptidomimetic enables efficient transport of proteins across brain endothelium.

Protein therapeutics cannot reach the brain in sufficient amounts because of their low permeability across the blood-brain barrier. Here we report a new family of bicyclic peptide shuttles, BrainBikes, capable of increasing transport of proteins, including antibody derivatives, in a human cell-based model of the blood-brain barrier.

Site-specific antibody masking enables conditional activation with different stimuli.

Antibody therapeutics show great potential to treat a variety of diseases. Often, the dose that can be safely administered is limited by side effects that arise from the interaction with the target outside the diseased tissue. Conditionally-active antibodies provide an additional layer of selectivity to improve safety.

Protease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics.

Peptides show high promise in the targeting and intracellular delivery of next-generation bio- and nano-therapeutics. However, the proteolytic susceptibility of peptides is one of the major limitations of their activity in biological environments. Numerous strategies have been devised to chemically enhance the resistance of peptides to proteolysis, ranging from - and -termini protection to cyclization, and including backbone modification, incorporation of amino acids with non-canonical side chains and conjugation.